Nuchal translucency as a predictor of adverse pregnancy outcome

International Journal of Gynecology and Obstetrics

Volumn 98, Issue 1, 2007, Pages 5-9

  Piazze, J ^a   Anceschi, M M ^a   Cerekja, A ^a   La Torre, R ^a   Pala, A ^b   Papa, A ^a   Cosmi, E V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

Nuchal translucency; Pregnancy outcome

Indexed keywords

ADULT; ADVERSE OUTCOME; AMNIOCENTESIS; ANEUPLOIDY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCHAL TRANSLUCENCY MEASUREMENT; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; SCREENING; STATISTICAL ANALYSIS;

EID: 34250175848     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2007.02.010     Document Type: Article

References (20)

1. Nicolaides K.H. First-trimester screening for chromosomal abnormalities. Semin Perinatol 29 (2005) 190-194
2. Michailidis G.D., and Economides D.L. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol 17 (2001) 102-105
3. Cheng C.C., Bahado-Singh R.O., Chen S.C., and Tsai M.S. Pregnancy outcomes with increased nuchal translucency after routine Down syndrome screening. Int J Gynecol Obstet 84 (2004) 5-9
4. Zimmermann R., Hucha A., Savoldelli G., Binket F., Achermann J., and Grudzinskas J.G. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities. Br J Obstet Gynaecol 103 (1996) 1009-1014
5. Tul N., Spencer K., Noble P., Chan C., and Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 19 (1999) 1035-1042
6. Spencer K., Ong C., Skentou H., Liao A.W., and Nicolaides K.H. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20 (2000) 411-416
7. Dugoff L., Hobbins J.C., Malone D.F., Porter T.F., Luthy D., Comstock C.H., et al. First trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (The FASTER Trial). Am J Obstet Gynecol 191 (2004) 1446-1451
8. Ruge S., Pedersen J.F., Sorensen S., and Lange A.P. Can pregnancy associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability?. Acta Obstet Gynecol Scand 69 (1990) 589-595
9. Nicolaides K.H., Brizot M.L., and Snijders R.J. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynaecol 101 (1994) 782-786
10. Nicolaides K.H., Heath V., and Cicero S. Increased fetal nuchal translucency at 11-14 weeks. Prenat Diagn 22 (2002) 308-315
11. Rutherford S.E., Phelan J.P., Smith C.V., and Jacobs N. The four-quadrant assessment of amniotic fluid volume: an adjunct to antepartum fetal heart rate testing. Obstet Gynecol 70 (1987) 353-356
12. Hughes G., Bischof P., Wilson G., and Klopper A. Assay of a placental protein to determine fetal risk. Br Med J 280 (1980) 671-673
13. Hughes G., Bischof P., Wilson G., Smith R., and Klopper A. Tests of fetal wellbeing in the third trimester of pregnancy. Br J Obstet Gynaecol 87 (1980) 650-656
14. Barnea E.R., Bischoff P., Page C., DeCherney A.H., Herrmann W., and Naftolin F. Placental and circulating pregnancy-associated plasma protein A concentrates in normal and pathological term pregnancies. Obstet Gynecol 68 (1986) 382-386
15. Yovich J.L., Willcox D.L., Grudzinskas J.G., and Bolton A.E. The prognostic value of HCG, PAPP-A, oestradiol-17 beta and progesterone in early human pregnancy. Aust N Z J Obstet Gynaecol 26 (1986) 59-64
16. Morssink L.P., Kornman L.H., Hallahan T.W., Kloosterman M.D., Beekhuis J.R., De Wolf B.T., et al. Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn 18 (1998) 147-152
17. Tsai M.S., Lee F.K., Cheng C.C., Hwa K.Y., Cheong M.L., and She B.Q. Association between fetal nuchal translucency thickness in first trimester and subsequent gestational hypertension and preeclampsia. Prenat Diagn 22 (2002) 747-751
18. Souka A.P., Von Kaisenberg C.S., Hyett J.A., Sonek J.D., and Nicolaides K.H. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 192 (2005) 1005-1021
19. Pajkrt E., Mol B.W., Bleker O.P., and Bilardo C.M. Pregnancy outcome and nuchal translucency measurements in fetuses with a normal karyotype. Prenat Diagn 19 (1999) 1104-1108
20. Krantz D., Goetzl L., Simpson J.L., Thom E., Zachary J., Hallahan T.W., et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 191 (2004) 1452-1458